• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丹参素通过减弱去卵巢诱导的骨质疏松症(GIO)大鼠的TXNIP信号通路来减轻微循环障碍和骨形成受损。

Tanshinol Alleviates Microcirculation Disturbance and Impaired Bone Formation by Attenuating TXNIP Signaling in GIO Rats.

作者信息

Lai Wenxiu, Mo Yulin, Wang Dongtao, Zhong Ying, Lu Lujiao, Wang Jiajia, Cui Liao, Liu Yanzhi, Yang Yajun

机构信息

Department of Pharmacology, Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong Medical University, Zhanjiang, China.

Department of Phamacy, Yuebei People's Hospital, Shaoguan, China.

出版信息

Front Pharmacol. 2021 Jul 14;12:722175. doi: 10.3389/fphar.2021.722175. eCollection 2021.

DOI:10.3389/fphar.2021.722175
PMID:34335280
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8316650/
Abstract

Impaired bone formation is the main characteristics of glucocorticoid (GC)-induced osteoporosis (GIO), which can be ameliorated by tanshinol, an aqueous polyphenol isolated from Bunge. However, the underlying mechanism is still not entirely clear. In the present study, we determined the parameters related to microstructure and function of bone tissue, bone microcirculation, and TXNIP signaling to investigate the beneficial effects of tanshinol on skeleton and its molecular mechanism in GIO rats. Male Sprague-Dawley rats aged 4 months were administrated orally with distilled water (Con), tanshinol (Tan, 25 mg kg d), prednisone (GC, 5 mg kg d) and GC plus tanshinol (GC + Tan) for 14 weeks. The results demonstrated that tanshinol played a significant preventive role in bone loss, impaired microstructure, dysfunction of bone metabolism and poor bone quality, based on analysis of correlative parameters acquired from the measurement by using Micro-CT, histomorphometry, ELISA and biomechanical assay. Tanshinol also showed a significant protective effect in bone microcirculation according to the evidence of microvascular perfusion imaging of cancellous bone in GIO rats, as well as the migration ability of human endothelial cells (EA.hy926, EA cells). Moreover, tanshinol also attenuated GC-elicited the activation of TXNIP signaling pathway, and simultaneously reversed the down-regulation of Wnt and VEGF pathway as manifested by using Western-blot method in GIO rats, EA cells, and human osteoblast-like MG63 cells (MG cells). Collectively, our data highlighted that tanshinol ameliorated poor bone health mediated by activation of TXNIP signaling inhibiting microcirculation disturbance and the following impaired bone formation in GIO rats.

摘要

骨形成受损是糖皮质激素(GC)诱导的骨质疏松症(GIO)的主要特征,而丹参素(从丹参中分离出的一种水溶性多酚)可改善这种情况。然而,其潜在机制仍不完全清楚。在本研究中,我们测定了与骨组织微观结构和功能、骨微循环以及TXNIP信号传导相关的参数,以研究丹参素对GIO大鼠骨骼的有益作用及其分子机制。将4月龄雄性Sprague-Dawley大鼠分别口服蒸馏水(Con)、丹参素(Tan,25 mg·kg·d)、泼尼松(GC,5 mg·kg·d)以及GC加丹参素(GC + Tan),持续14周。基于使用Micro-CT、组织形态计量学、ELISA和生物力学测定所获得的相关参数分析,结果表明丹参素在骨质流失、微观结构受损、骨代谢功能障碍和骨质不佳方面发挥了显著的预防作用。根据GIO大鼠松质骨微血管灌注成像以及人内皮细胞(EA.hy926,EA细胞)迁移能力的证据,丹参素在骨微循环方面也显示出显著的保护作用。此外,丹参素还减弱了GC引发的TXNIP信号通路的激活,同时在GIO大鼠、EA细胞和人成骨样MG63细胞(MG细胞)中,通过蛋白质免疫印迹法显示其逆转了Wnt和VEGF通路的下调。总体而言,我们的数据突出表明,丹参素通过抑制微循环紊乱以及随后GIO大鼠中受损的骨形成,改善了由TXNIP信号激活介导的不良骨骼健康状况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/b568c4712a15/fphar-12-722175-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/7c1d7fb02b0a/fphar-12-722175-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/df89e91bda52/fphar-12-722175-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/734319491420/fphar-12-722175-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/18e2542ebc26/fphar-12-722175-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/c49f8c7458ef/fphar-12-722175-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/cd005e3745a1/fphar-12-722175-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/0580bbb6a84c/fphar-12-722175-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/f966883828a3/fphar-12-722175-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/b568c4712a15/fphar-12-722175-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/7c1d7fb02b0a/fphar-12-722175-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/df89e91bda52/fphar-12-722175-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/734319491420/fphar-12-722175-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/18e2542ebc26/fphar-12-722175-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/c49f8c7458ef/fphar-12-722175-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/cd005e3745a1/fphar-12-722175-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/0580bbb6a84c/fphar-12-722175-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/f966883828a3/fphar-12-722175-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f58/8316650/b568c4712a15/fphar-12-722175-g009.jpg

相似文献

1
Tanshinol Alleviates Microcirculation Disturbance and Impaired Bone Formation by Attenuating TXNIP Signaling in GIO Rats.丹参素通过减弱去卵巢诱导的骨质疏松症(GIO)大鼠的TXNIP信号通路来减轻微循环障碍和骨形成受损。
Front Pharmacol. 2021 Jul 14;12:722175. doi: 10.3389/fphar.2021.722175. eCollection 2021.
2
Tanshinol alleviates impaired bone formation by inhibiting adipogenesis via KLF15/PPARγ2 signaling in GIO rats.丹参醇通过抑制 GIO 大鼠中 KLF15/PPARγ2 信号通路的脂肪生成来缓解成骨作用受损。
Acta Pharmacol Sin. 2018 Apr;39(4):633-641. doi: 10.1038/aps.2017.134. Epub 2018 Jan 11.
3
Tanshinol Rescues the Impaired Bone Formation Elicited by Glucocorticoid Involved in KLF15 Pathway.丹参醇挽救由糖皮质激素引发的、涉及KLF15通路的骨形成受损。
Oxid Med Cell Longev. 2016;2016:1092746. doi: 10.1155/2016/1092746. Epub 2016 Mar 14.
4
Salvianolic acid B prevents bone loss in prednisone-treated rats through stimulation of osteogenesis and bone marrow angiogenesis.丹酚酸 B 通过刺激成骨和骨髓血管生成预防泼尼松治疗大鼠的骨丢失。
PLoS One. 2012;7(4):e34647. doi: 10.1371/journal.pone.0034647. Epub 2012 Apr 6.
5
Tanshinol Alleviates Osteoporosis and Myopathy in Glucocorticoid-Treated Rats.丹参醇减轻糖皮质激素处理大鼠的骨质疏松和肌病。
Planta Med. 2017 Nov;83(16):1264-1273. doi: 10.1055/s-0043-108761. Epub 2017 Apr 20.
6
TXNIP contributes to bone loss via promoting the mitochondrial oxidative phosphorylation during glucocorticoid-induced osteoporosis.TXNIP 通过促进糖皮质激素诱导性骨质疏松症过程中的线粒体氧化磷酸化作用导致骨丢失。
Life Sci. 2021 Feb 1;266:118938. doi: 10.1016/j.lfs.2020.118938. Epub 2020 Dec 19.
7
Tanshinol stimulates bone formation and attenuates dexamethasone-induced inhibition of osteogenesis in larval zebrafish.丹参醇刺激幼体斑马鱼的骨形成并减弱地塞米松诱导的成骨抑制作用。
J Orthop Translat. 2015 Sep 2;4:35-45. doi: 10.1016/j.jot.2015.07.002. eCollection 2016 Jan.
8
Z-Guggulsterone attenuates glucocorticoid-induced osteoporosis through activation of Nrf2/HO-1 signaling.Z-姜黄素通过激活 Nrf2/HO-1 信号通路减轻糖皮质激素诱导的骨质疏松症。
Life Sci. 2019 May 1;224:58-66. doi: 10.1016/j.lfs.2019.03.051. Epub 2019 Mar 21.
9
Polygonum multiflorm alleviates glucocorticoid‑induced osteoporosis and Wnt signaling pathway.多花蓼缓解糖皮质激素诱导的骨质疏松症及 Wnt 信号通路。
Mol Med Rep. 2018 Jan;17(1):970-978. doi: 10.3892/mmr.2017.7997. Epub 2017 Nov 7.
10
miR-133a silencing rescues glucocorticoid-induced bone loss by regulating the MAPK/ERK signaling pathway.miR-133a 沉默通过调节 MAPK/ERK 信号通路来挽救糖皮质激素诱导的骨丢失。
Stem Cell Res Ther. 2021 Mar 29;12(1):215. doi: 10.1186/s13287-021-02278-w.

引用本文的文献

1
An electrostatic encapsulation strategy to motivate 3D-printed polyelectrolyte scaffolds for repair of osteoporotic bone defects.一种用于激发3D打印聚电解质支架修复骨质疏松性骨缺损的静电封装策略。
Bioact Mater. 2024 Dec 7;46:1-20. doi: 10.1016/j.bioactmat.2024.12.007. eCollection 2025 Apr.
2
Salvia miltiorrhiza in osteoporosis: a review of its phytochemistry, traditional clinical uses and preclinical studies (2014-2024).丹参在骨质疏松症中的应用:对其植物化学、传统临床应用及临床前研究的综述(2014 - 2024年)
Front Pharmacol. 2024 Oct 3;15:1483431. doi: 10.3389/fphar.2024.1483431. eCollection 2024.
3
Alendronate Functionalized Bone-Targeting Pomolic Acid Liposomes Restore Bone Homeostasis for Osteoporosis Treatment.

本文引用的文献

1
Role of Thioredoxin-Interacting Protein in Diseases and Its Therapeutic Outlook.硫氧还蛋白相互作用蛋白在疾病中的作用及其治疗前景。
Int J Mol Sci. 2021 Mar 9;22(5):2754. doi: 10.3390/ijms22052754.
2
Long non-coding RNA MEG3 silencing and microRNA-214 restoration elevate osteoprotegerin expression to ameliorate osteoporosis by limiting TXNIP.长非编码 RNA MEG3 沉默和 microRNA-214 恢复通过限制 TXNIP 来提高骨保护素的表达,从而改善骨质疏松症。
J Cell Mol Med. 2021 Feb;25(4):2025-2039. doi: 10.1111/jcmm.16096. Epub 2021 Jan 3.
3
TXNIP contributes to bone loss via promoting the mitochondrial oxidative phosphorylation during glucocorticoid-induced osteoporosis.
阿仑膦酸盐功能化骨靶向熊果酸脂质体恢复骨质疏松治疗的骨稳态。
Int J Nanomedicine. 2024 Aug 6;19:7983-7996. doi: 10.2147/IJN.S462514. eCollection 2024.
4
Tanshinol ameliorates imiquimod-induced psoriasis by inhibiting M1 macrophage polarization through suppression of the notch signaling pathway.丹参醇通过抑制 Notch 信号通路抑制 M1 巨噬细胞极化来改善咪喹莫特诱导的银屑病。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):8745-8758. doi: 10.1007/s00210-024-03166-9. Epub 2024 Jun 4.
5
KLF transcription factors in bone diseases.KLF 转录因子在骨骼疾病中的作用。
J Cell Mol Med. 2024 Apr;28(8):e18278. doi: 10.1111/jcmm.18278.
6
Expanding the therapeutic potential of : a review of its pharmacological applications in musculoskeletal diseases.拓展[药物名称未给出]的治疗潜力:其在肌肉骨骼疾病中的药理学应用综述
Front Pharmacol. 2023 Dec 5;14:1276038. doi: 10.3389/fphar.2023.1276038. eCollection 2023.
7
Editorial: Recent trends in pharmacological treatment of musculoskeletal disorders.社论:肌肉骨骼疾病药物治疗的最新趋势
Front Pharmacol. 2022 Sep 2;13:908977. doi: 10.3389/fphar.2022.908977. eCollection 2022.
8
Thioredoxin-interacting protein: A new therapeutic target in bone metabolism disorders?硫氧还蛋白相互作用蛋白:骨代谢紊乱的新治疗靶点?
Front Immunol. 2022 Aug 17;13:955128. doi: 10.3389/fimmu.2022.955128. eCollection 2022.
9
Antiosteoporosis effect of tanshinol in osteoporosis animal models: A systematic review and meta-analysis.丹参醇在骨质疏松动物模型中的抗骨质疏松作用:一项系统评价与荟萃分析。
Front Pharmacol. 2022 Aug 10;13:937538. doi: 10.3389/fphar.2022.937538. eCollection 2022.
TXNIP 通过促进糖皮质激素诱导性骨质疏松症过程中的线粒体氧化磷酸化作用导致骨丢失。
Life Sci. 2021 Feb 1;266:118938. doi: 10.1016/j.lfs.2020.118938. Epub 2020 Dec 19.
4
Bone Vasculature and Bone Marrow Vascular Niches in Health and Disease.骨血管和骨髓血管龛在健康和疾病中的作用。
J Bone Miner Res. 2020 Nov;35(11):2103-2120. doi: 10.1002/jbmr.4171. Epub 2020 Sep 23.
5
Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action.鉴定一种具有抗糖尿病作用、可口服的小分子化合物,该化合物可调节 TXNIP 的表达和胰高血糖素的作用。
Cell Metab. 2020 Sep 1;32(3):353-365.e8. doi: 10.1016/j.cmet.2020.07.002. Epub 2020 Jul 28.
6
Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment.糖皮质激素性骨质疏松症的发病机制与治疗选择。
Nat Rev Endocrinol. 2020 Aug;16(8):437-447. doi: 10.1038/s41574-020-0341-0. Epub 2020 Apr 14.
7
Type H blood vessels in bone modeling and remodeling.骨改建和重塑中的 H 型血管。
Theranostics. 2020 Jan 1;10(1):426-436. doi: 10.7150/thno.34126. eCollection 2020.
8
Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy.合成代谢药物在糖皮质激素诱导性骨质疏松症管理中的应用:基于证据的长期安全性、疗效及治疗地位综述
Core Evid. 2019 Aug 23;14:41-50. doi: 10.2147/CE.S172820. eCollection 2019.
9
Role of angiocrine signals in bone development, homeostasis and disease.血管分泌信号在骨骼发育、稳态和疾病中的作用。
Open Biol. 2019 Oct 31;9(10):190144. doi: 10.1098/rsob.190144. Epub 2019 Oct 2.
10
Targeting Cell Senescence for the Treatment of Age-Related Bone Loss.靶向细胞衰老治疗与年龄相关的骨质流失。
Curr Osteoporos Rep. 2019 Apr;17(2):70-85. doi: 10.1007/s11914-019-00504-2.